Aethlon Medical Inc. 10-Q Summary (Period Ended June 30, 2011)
Business Context and Reporting Period
Aethlon Medical, Inc. is a development-stage medical device company focused on the ADAPT system, a therapeutic filtration device for removing harmful particles from the circulatory system. The company has not yet generated significant revenue from principal operations and requires FDA approval for its Hemopurifier device. This report covers the three-month period ended June 30, 2011.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2011 | Three Months Ended June 30, 2010 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Expenses | $1,032,480 | $1,162,307 |
| Net Loss | $(2,585,901) | $(3,495,265) |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.05) |
| Cash and Cash Equivalents (End of Period) | $13,417 | $63,593 |
| Net Cash Used in Operating Activities | $(540,552) | $(362,082) |
| Total Current Liabilities | $7,027,596 | N/A |
| Derivative Liabilities | $2,221,224 | N/A |
| Accumulated Deficit (Inception to Date) | $(51,057,847) | N/A |
Material Changes vs. Prior Period
- Operating Expenses: Decreased by approximately $130,000 (11.2%) compared to the prior year quarter. This reduction was primarily driven by a $491,377 non-cash stock option extension charge in the prior year that did not recur, partially offset by increased professional fees related to clinical trials.
- Other Expenses: Decreased significantly due to the absence of a $2.2 million loss on debt extinguishment recorded in the prior year. However, interest expense increased by approximately $1.1 million due to accelerated amortization of debt discounts and adjustments to derivative liabilities.
- Liquidity: Cash on hand decreased from $15,704 to $13,417. Negative working capital widened to approximately $6.86 million.
- Debt Structure: The company issued new convertible notes and converted existing debt into equity ($1.2 million principal converted to 14.1 million shares) during the quarter.
Outlook, Risks, and Management Commentary
- Going Concern: Management explicitly states that the financial statements are prepared on a going concern basis, which raises significant doubt about the company's ability to continue operations. Current resources are insufficient to fund operations for the fiscal year ending March 31, 2012.
- Capital Needs: The company requires a minimum of $180,000 per month to sustain operations and is actively seeking additional debt or equity financing. No assurance is given that funds will be raised.
- Debt Defaults: As of June 30, 2011, approximately $1.57 million in promissory and convertible notes were past due and in default. The company has accrued $437,800 in liquidated damages related to registration payment failures.
- Regulatory Status: The company has submitted an Investigational Device Exemption (IDE) to the FDA but has not yet received approval to begin human trials.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of the end of the period.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to raise the required $180,000 monthly operating budget given the current cash balance of only $13,417.
- Debt Settlement: Confirm the status of the $1.57 million in defaulted notes and the potential for further dilution or legal action.
- Derivative Liability Volatility: Monitor the $2.2 million derivative liability, which fluctuates based on stock price and significantly impacts reported net loss.
- Regulatory Milestones: Track the status of the FDA IDE submission and the timeline for potential human trials.
- Dilution Risk: Assess the impact of outstanding warrants (approx. 47 million) and convertible notes on future share count.